Status:
UNKNOWN
Dexamethasone Efficacy in HELLP I Syndrome
Lead Sponsor:
Universidad del Valle, Colombia
Conditions:
HELLP Syndrome
Eligibility:
FEMALE
10-48 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy of dexamethasone for treatment of HELLP I (hemolysis, elevated liver enzymes and low platelet count) syndrome.
Detailed Description
Treatment of HELLP syndrome usually is restricted to measures of support and treatment of complications. In 2005, in a subgroup analysis we showed that, among patients with HELLP 1, there were a short...
Eligibility Criteria
Inclusion
- Women who were at \>20 weeks of gestation or during the first 3 days of puerperium if hypertension developed during the pregnancy or the puerperium with:
- platelet count, \< or = 50,000/mm3; aspartate aminotransferase (AST), \> or = 70 U/L; lactate dehydrogenase (LDH), \> or = 600 U/L.
- Women who consent to be included informed consent by signature
Exclusion
- diabetic ketoacidosis
- oral temperature \> 37.5 grade
- Contraindication for use steroids
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01138839
Start Date
October 1 2009
End Date
December 1 2012
Last Update
June 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad del Valle
Cali, Valle del Cauca Department, Colombia, 57